Dariohealth Corp. current report, 02 July 2019

Business Context and Reporting Period

This Form 8-K was filed by DarioHealth Corp. on July 2, 2019, reporting events occurring on the same date. The company is an emerging growth company incorporated in Delaware with principal executive offices in Israel. Its common stock (DRIO) and warrants (DRIOW) trade on The Nasdaq Capital Market.

Key Financial Metrics

The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial disclosure is an estimate regarding stockholders' equity.

  • Stockholders' Equity: Management believes total stockholders' equity exceeded $5 million as of June 27, 2019.
  • Cash Resources: The equity estimate incorporates proceeds from an underwritten public offering that closed on May 24, 2019.

Material Changes

The filing highlights a material change in the company's capital structure resulting from the closing of its underwritten public offering on May 24, 2019. This event is the basis for the company's assertion that it has met the $5 million stockholders' equity threshold required to maintain its listing status.

Guidance, Outlook, and Risks

The filing contains forward-looking statements regarding the company's equity position, which are subject to significant uncertainties. Management explicitly warns that actual results may differ materially due to various factors, including:

  • Regulatory approvals and product demand.
  • Market acceptance and competitive pressures.
  • Product development and commercialization difficulties.
  • Technological challenges and legal risks.
  • The adequacy of existing cash resources.

The company undertakes no obligation to update these forward-looking statements.

Investor Verification Checklist

  • Verify the final audited stockholders' equity figure in the subsequent 10-Q or 10-K to confirm the $5 million threshold was met.
  • Review the prospectus for the May 24, 2019 public offering to confirm the exact proceeds received.
  • Monitor the company's cash burn rate and runway given the risks associated with the adequacy of cash resources.
  • Check for any regulatory updates regarding the company's medical device products.